GT Biopharma Inc
GTBP
Company Profile
Business description
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
Contact
315 Montgomery Street
10th Floor
San FranciscoCA94104
USASector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
1
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,652.20 | 27.30 | 0.32% |
| CAC 40 | 7,788.10 | 38.69 | -0.49% |
| DAX 40 | 24,038.19 | 188.30 | -0.78% |
| Dow JONES (US) | 42,098.70 | 244.95 | -0.58% |
| FTSE 100 | 8,726.01 | 52.04 | -0.59% |
| HKSE | 23,315.86 | 57.55 | 0.25% |
| NASDAQ | 19,100.94 | 98.22 | -0.51% |
| Nikkei 225 | 38,355.70 | 633.30 | 1.68% |
| NZX 50 Index | 12,297.78 | 64.48 | -0.52% |
| S&P 500 | 5,888.55 | 32.99 | -0.56% |
| S&P/ASX 200 | 8,425.10 | 28.20 | 0.34% |
| SSE Composite Index | 3,361.83 | 21.90 | 0.66% |